WO2020177729A1 - Dérivé cyclique aromatique fusionné, procédé de préparation correspondant et utilisation pharmaceutique associée - Google Patents

Dérivé cyclique aromatique fusionné, procédé de préparation correspondant et utilisation pharmaceutique associée Download PDF

Info

Publication number
WO2020177729A1
WO2020177729A1 PCT/CN2020/077890 CN2020077890W WO2020177729A1 WO 2020177729 A1 WO2020177729 A1 WO 2020177729A1 CN 2020077890 W CN2020077890 W CN 2020077890W WO 2020177729 A1 WO2020177729 A1 WO 2020177729A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
cycloalkyl
alkyl
general formula
amino
Prior art date
Application number
PCT/CN2020/077890
Other languages
English (en)
Chinese (zh)
Inventor
张晓敏
张睿
王珏
贺峰
陶维康
Original Assignee
江苏恒瑞医药股份有限公司
上海恒瑞医药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江苏恒瑞医药股份有限公司, 上海恒瑞医药有限公司 filed Critical 江苏恒瑞医药股份有限公司
Priority to CN202080005992.0A priority Critical patent/CN112955432B/zh
Publication of WO2020177729A1 publication Critical patent/WO2020177729A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un dérivé cyclique aromatique fusionné, un procédé de préparation correspondant et une utilisation pharmaceutique associée. En particulier, la présente invention concerne un dérivé cyclique aromatique fusionné représenté par la formule générale (I), un procédé de préparation correspondant, une composition pharmaceutique contenant le dérivé, une utilisation de celui-ci en tant qu'inhibiteur d'ATX, et une utilisation de celui-ci dans la préparation d'un médicament pour le traitement d'un cancer ou d'une maladie ou d'un trouble de dégénérescence fibreuse. Chaque substituant dans la formule générale (I) est tel que défini dans la description.
PCT/CN2020/077890 2019-03-06 2020-03-05 Dérivé cyclique aromatique fusionné, procédé de préparation correspondant et utilisation pharmaceutique associée WO2020177729A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202080005992.0A CN112955432B (zh) 2019-03-06 2020-03-05 稠合芳香环类衍生物、其制备方法及其在医药上的应用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201910169283 2019-03-06
CN201910169283.5 2019-03-06
CN201911374834.8 2019-12-27
CN201911374834 2019-12-27

Publications (1)

Publication Number Publication Date
WO2020177729A1 true WO2020177729A1 (fr) 2020-09-10

Family

ID=72337609

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/077890 WO2020177729A1 (fr) 2019-03-06 2020-03-05 Dérivé cyclique aromatique fusionné, procédé de préparation correspondant et utilisation pharmaceutique associée

Country Status (3)

Country Link
CN (1) CN112955432B (fr)
TW (1) TW202100512A (fr)
WO (1) WO2020177729A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493453A (zh) * 2020-04-07 2021-10-12 江苏恒瑞医药股份有限公司 稠合芳香环类衍生物、其制备方法及其在医药上的应用
WO2022007882A1 (fr) * 2020-07-09 2022-01-13 苏州爱科百发生物医药技术有限公司 Inhibiteur d'atx, son procédé de préparation et son utilisation
WO2022135590A1 (fr) * 2020-12-27 2022-06-30 上海凌达生物医药有限公司 Composés pyrimido-hétérocycliques, et leur procédé de préparation et leur utilisation
WO2023093832A1 (fr) * 2021-11-25 2023-06-01 上海济煜医药科技有限公司 Dérivé tricyclique et procédé de préparation s'y rapportant et application associée
US11820747B2 (en) 2021-11-02 2023-11-21 Flare Therapeutics Inc. PPARG inverse agonists and uses thereof
US11912668B2 (en) 2020-11-18 2024-02-27 Deciphera Pharmaceuticals, Llc GCN2 and perk kinase inhibitors and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996036633A1 (fr) * 1995-05-17 1996-11-21 E.I. Du Pont De Nemours And Company Amides cycliques fongiques
WO1997000612A1 (fr) * 1995-06-20 1997-01-09 E.I. Du Pont De Nemours And Company Amides cycliques arthropodicides et fongicides
WO1998005652A2 (fr) * 1996-08-01 1998-02-12 E.I. Du Pont De Nemours And Company Amides cycliques arthropodicides et fongicides
WO1998023155A1 (fr) * 1996-11-26 1998-06-04 E.I. Du Pont De Nemours And Company Amides cycliques arthropodicides et fongicides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996036633A1 (fr) * 1995-05-17 1996-11-21 E.I. Du Pont De Nemours And Company Amides cycliques fongiques
WO1997000612A1 (fr) * 1995-06-20 1997-01-09 E.I. Du Pont De Nemours And Company Amides cycliques arthropodicides et fongicides
WO1998005652A2 (fr) * 1996-08-01 1998-02-12 E.I. Du Pont De Nemours And Company Amides cycliques arthropodicides et fongicides
WO1998023155A1 (fr) * 1996-11-26 1998-06-04 E.I. Du Pont De Nemours And Company Amides cycliques arthropodicides et fongicides

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493453A (zh) * 2020-04-07 2021-10-12 江苏恒瑞医药股份有限公司 稠合芳香环类衍生物、其制备方法及其在医药上的应用
CN113493453B (zh) * 2020-04-07 2023-06-16 江苏恒瑞医药股份有限公司 稠合芳香环类衍生物、其制备方法及其在医药上的应用
WO2022007882A1 (fr) * 2020-07-09 2022-01-13 苏州爱科百发生物医药技术有限公司 Inhibiteur d'atx, son procédé de préparation et son utilisation
US11912668B2 (en) 2020-11-18 2024-02-27 Deciphera Pharmaceuticals, Llc GCN2 and perk kinase inhibitors and methods of use thereof
WO2022135590A1 (fr) * 2020-12-27 2022-06-30 上海凌达生物医药有限公司 Composés pyrimido-hétérocycliques, et leur procédé de préparation et leur utilisation
US11820747B2 (en) 2021-11-02 2023-11-21 Flare Therapeutics Inc. PPARG inverse agonists and uses thereof
WO2023093832A1 (fr) * 2021-11-25 2023-06-01 上海济煜医药科技有限公司 Dérivé tricyclique et procédé de préparation s'y rapportant et application associée

Also Published As

Publication number Publication date
TW202100512A (zh) 2021-01-01
CN112955432A (zh) 2021-06-11
CN112955432B (zh) 2022-11-22

Similar Documents

Publication Publication Date Title
WO2020177729A1 (fr) Dérivé cyclique aromatique fusionné, procédé de préparation correspondant et utilisation pharmaceutique associée
CN114630823A (zh) Glp-1r调节化合物
JP5658664B2 (ja) １，２−二置換複素環式化合物
WO2021027911A1 (fr) Nouvel inhibiteur de k-ras g12c spirocyclique
CN112312904A (zh) 螺环化合物
CN103153994A (zh) 双环杂芳基激酶抑制剂及使用方法
CN114846005A (zh) Shp2抑制剂及其应用
TWI785474B (zh) 用作選擇性Aurora A抑制劑的新型雜環化合物
CN111333648B (zh) 8-取代的芳香环乙烯基黄嘌呤衍生物及其用途
WO2021139775A1 (fr) Composé de pyridone et son application
TW201315727A (zh) 尿嘧啶衍生物及其醫藥用途
WO2020244539A1 (fr) Dérivé de pyridone, son procédé de préparation et son application pharmaceutique
WO2021208918A1 (fr) Composés tricycliques servant d'inhibiteurs d'egfr
WO2021164746A1 (fr) Composé aryle substitué
CN113387962A (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
CN110981876B (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
WO2020192750A1 (fr) Dérivé thiénohétérocyclique, son procédé de préparation et son utilisation médicale
TW202110848A (zh) 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用
JP2022511236A (ja) 置換キナゾリノン誘導体、及びｍＧｌｕＲ４のポジティブアロステリック調節剤としてのその使用
CN113493453B (zh) 稠合芳香环类衍生物、其制备方法及其在医药上的应用
CN112300165B (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
WO2022171088A1 (fr) Dérivé de pyrazolo[3,4-d]pyrimidin-3-one
CN111072676B (zh) 含氮稠合三环衍生物及其用途
CN111018856B (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN110922408B (zh) 3H-[1,2,3]三唑并[4,5-d]嘧啶-5-胺衍生物及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20766926

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20766926

Country of ref document: EP

Kind code of ref document: A1